Clinical data and serum 25-hydroxyvitamin D (25OHD) levels of patients with systemic sclerosis (SSc; n = 137) [limited type (n = 76, 55.5%); diffuse type (n = 61, 44.5%)].
| Characteristic | |
|---|---|
| 25OHD*, median (range), ng/ml | 13.1 (4.1–47.8) |
| < 10 ng/ml | 49 (137/35.8%) |
| ≥ 10 < 30 ng/ml | 74 (137/54%) |
| ≥ 30 ng/ml | 14 (137/10.2%) |
| Male/female | 18/119 (13.1%/86.9%) |
| Age, yrs, mean ± SD | 56 ± 13.6 |
| Antibodies (%) | |
| No antibodies | 22 (16.1) |
| ANA without specific antibodies | 30 (21.9) |
| Anticentromere | 58 (42.3) |
| SCL-70 | 27 (19.7) |
| Digital ulcers (%) | |
| No ulcers | 103 (75.2) |
| Active ulcers | 17 (12.4) |
| History of ulcers | 17 (12.4) |
| Kidney disease (%) | |
| Yes | 4 (2.9) |
| No | 133 (97.1) |
| GERD (%) | |
| Yes | 73 (53.3) |
| No | 64 (46.7) |
| Lung fibrosis (%) | |
| Yes | 73 (53.3) |
| No | 64 (46.7) |
| Modified Rodnan skin score, mean ± SD | 10.1 ± 7.3 |
| Body mass index, median (range) | 24 (13–43) |
| Treatment (%) | |
| No therapy | 55 (40.1) |
| MTX or azathioprine | 14 (10.2) |
| Corticosteroids | 17 (12.4) |
| Corticosteroids plus MTX or azathioprine | 14 (10.2) |
| Other therapy or combination | 37 (27.1) |
↵* Excluding 4 cases with 25OHD levels < 4 ng/ml. GERD: gastroesophageal reflux disease; MTX: methotrexate; ANA: antinuclear antibody.